Puretech Health Share Discussion Threads

[volvo] 04/8/2021 19:05

Spoke to the company last night......it was highlighted to myself that directors are are buying and in next 4 months the newsflow is set to be massive.....ok i doubled again today sub 330p, watch and see

[volvo] 28/7/2021 16:01

lmaf been watching trades for a month or so, and I like what I am seeing.....share price being controlled irrespective of the ongoing positive news, I like that, normally means outside powers are taking an interest imo. dyor

[lendmeafiver] 27/7/2021 21:46

Agree Volvo, it’s all upside given cash and near cash resources, good timing I think, I only got back in over the last week or so after a good run in a cracking logistics company, thanks for that.

[volvo] 27/7/2021 18:36

In the Nasdaq set, Vedanta is the eagerly awaited ipo.....they raised $68m for fun recently.

[volvo] 27/7/2021 18:21

lmf only back here to make money, talked to the company last week, all blue sky, so had to have abit, doubled position before the close

[lendmeafiver] 27/7/2021 17:55

Good to see you back Volvo

[volvo] 27/7/2021 15:49

Coco, re valuation, if we can see the under valuation so can others and any listed company is up for sale.....maybe the directors are loading up before a bid, the Americans are dripping in cash atm

[volvo] 27/7/2021 15:43

Back in today with 7500 shares at 332p.

Think you will see the Vedanta ipo sooner rather than later.

.....and Vedanta is looking like the 'jewel in the crown', going to start at $2b on the Nasdaq maybe more

[coco2020] 22/7/2021 08:03

Thanks Rambutan.

I think Jeffries are way off the mark and are totally undervaluing Puretech. This is from tones77777 post on LSE earlier this week.

‘ Current mcap - £925m ($1.26b)

Cash as at March 2021 - $486m
8.2% Stake in founded entity, Karuna (listed) - $270m (based on Kaurna's marketcap today of $3.3bn)
19.3% Stake in founded entity, Gelesis (soon to be listed - today's news) - $247m (based on IPO implied market value of $1.3bn)
8.6% Stake in founded entity, Vor BioPharma (listed) - $50m (based on Vor's marketcap today of $582m)

Adding these liquid cash/and assets equates to a total of $1.05bn. That essentially translates to 85% of the markecap is valuing just cash and liquid assets in these founding entities. This essentially means the wholly owned pipeline of products at Puretech and a host of other holdings including Follica, Akili, Vedanta and Sonde are all valued at just $210m!!’

I understand that the valuation for Vedanta Biosciences are mulled to be between $1-1.5bn and PRTC has a 50% stake. When that IPO’s later this year, the current mcap/valuation that already looks silly, will look absolutely comical!
So much value to be had here but clearly Peel Hunt seem to value this more reasonably at near the 1000p than Jeffries!

[rambutan2] 21/7/2021 15:55

And from Cit ywire this morning:

The planned listing of Gelesis is set to deliver significant upside to its founder PureTech Health (PRTC), a US-based biotechnology company which spins out businesses based on successful drugs, and is indicative of the latent value in its portfolio, says Jefferies.

Analyst Peter Welford maintained a Buy recommendation and set a target price of 510p on PureTech, which closed down 0.3%, or 0.1p, at 323p on Tuesday.

Gelesis, which has a US-approved weight-management drug to tackle obesity, is set go public on the New York Stock Exchange via a SPAC with an implied post-money enterprise value of $1bn (£730m).

That suggests PureTech’s 19.2% stake before the transaction is worth around $190m, a circa 40% upside from the broker’s previous estimate.

"We estimate the Karuna and Vor stakes, plus net cash underpin circa 60% of the current share price, which along with potential Gelesis upside, suggests the substantial value of multiple internal and portfolio opportunities is under appreciated," said Welford.

The analyst said he believes there is "more to come" from equity stakes in nine founded entities. "Significant value can be realised from these, in our view, but without typical single product binary risk," he added.

[rambutan2] 21/7/2021 15:49

And the good news keeps flowing:

Vedanta Biosciences Completes $68 Million Series D Financing

Proceeds expected to be used primarily to support a Phase 3 trial of lead candidate VE303 in Clostridioides difficile infection (CDI) and a Phase 2 trial of VE202 in inflammatory bowel disease (IBD)

Topline data from Phase 2 trial of VE303 in CDI are anticipated in Q3 2021

Plans to initiate Phase 2 trial of VE202 for treatment of mild to moderate ulcerative colitis in H2 2021

CAMBRIDGE, MA, July 21, 2021 – Vedanta Biosciences, Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced the closing of a $68 million Series D financing and provided a pipeline update.

The Series D financing was led by affiliates of Magnetar Capital. Other participants in the financing were new and existing investors including Verition Fund Management, Fosun Health Capital, co-founder PureTech Health, Rock Springs Capital, Skyviews Life Science, JSR Corporation, SymBiosis LLC, Shumway Capital, Health for Life Capital (Seventure Partners), and other institutional investors. The round also includes a $25 million investment from Pfizer as part of the Pfizer Breakthrough Growth Initiative, which was announced in January 2021.

Vedanta plans to use the proceeds to advance its pipeline of defined bacterial consortia, including progressing VE303 into a Phase 3 clinical trial in patients at high risk for recurrent CDI, initiating a Phase 2 clinical trial of VE202 in mild to moderate ulcerative colitis, and continuing to advance programs in additional indications.

“We are delighted to welcome the new investors in our Series D round and are grateful to our existing shareholders and partners for their continued support,” said Bernat Olle, Ph.D., Co-Founder and Chief Executive Officer of Vedanta Biosciences. “Since our last funding round, we have made significant progress advancing defined bacterial consortia as a new modality for infectious and immune-mediated diseases. This most recent financing, together with the support we receive from BARDA for our CDI program, will enable us to advance mid- and late-stage programs in CDI and IBD, as well as support early exploratory clinical studies in additional indications.”

“Drugs based on defined bacterial consortia are a promising new therapeutic modality with the potential to transform medicine, and Vedanta is the leader in this category, with a state-of-the-art discovery platform, field-leading GMP manufacturing capabilities, and an advanced pipeline,” said Ted Koutouzis, M.D., Managing Director of Fiscus Venture and Reimagined Ventures, affiliates of Magnetar. “We are proud to support the company’s efforts.”

[lendmeafiver] 20/7/2021 09:33

Thanks Ed, couldn't believe how much this had fallen with so much good news flow, makes absolutely no sense at all.

[edwardt] 20/7/2021 09:25

Good to have you back.

[lendmeafiver] 19/7/2021 14:28

Bought back in here, after recent news, including more today, this is remarkable value in my view.

[af004] 13/7/2021 07:31

Write up in daily mail yesterday.

[lendmeafiver] 12/7/2021 16:35

Great news flow over the last week, largely unnoticed by the market.

[rambutan2] 08/7/2021 22:30

Such interesting tech:

BOSTON — July, 8 2021 — Sonde Health announced that it will work with leading chipmaker Qualcomm Technologies, Inc. to optimize Sonde’s vocal biomarker technology for use with the flagship and high-tier Qualcomm® Snapdragon™ 888 and 778G 5G Mobile Platforms to help bring native, machine learning-driven vocal biomarker capabilities to mobile and IoT devices globally. The optimization has the potential to unlock several native health screening and monitoring applications on hundreds of millions of mobile devices that use these Snapdragon mobile platforms.

“Imagine a car that can detect whether a driver is too impaired to drive safely, or a home hub that can detect the onset of depression, or a phone that can make continuous asthma assessments. Bringing the vocal biomarker technology directly into mobile hardware will make new health features more useful and secure,” said David Liu, CEO at Sonde Health. “This collaboration marks a tremendous boost to our growth strategy, a vote of confidence in our technology, and a giant leap forward for preventive and personalized health care.”

Sonde will work with Qualcomm Technologies to introduce Sonde’s capabilities and technology concept to Qualcomm Technologies’ mobile and IoT customers as part of the collaboration.

[zipstuck] 30/6/2021 09:03

Re-assurance from Vedanta

[edwardt] 28/6/2021 08:20

nice to see insider buying.

[rambutan2] 17/6/2021 15:52

Yesterday's Alivio buy back makes sense with regards to the internal pipeline push:

[edwardt] 17/6/2021 15:44

enjoyed that chat. the more i listen to her - the more convincing she becomes!

[rambutan2] 10/6/2021 21:32

The two most recent webcast presentations, with Liberum and with Jefferies are quite good I thought, with the internal pipeline starting to sound really rather exciting:

[mighunter] 10/6/2021 12:37

Liberum mark Puretech as joint top pick in medical sector this morning (other is Medica MGP), reiterating PRTC buy with PT of 540p.

[edwardt] 27/5/2021 07:06

Little on implied valuation but it is clearly backed by a who's who of successful vc investors...